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Tetracyclic coreHerein, we describe our research efforts to develop unique cores in molecules which function as HCV
nonstructural protein 5A (NS5A) inhibitors. In particular, various fused tetracyclic cores were identified
which showed genotype and mutant activities comparable to the indole-based tetracyclic core.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Hepatitis C virus (HCV) is currently the leading cause of chronic
liver disease and has become the most common blood-borne infec-
tion in developed countries.1 Recent estimates of disease burden
show an increase in seroprevalence over the last 15 years to 2.8%
worldwide, equating to 185 million infections.2 If left untreated,
HCV can result in debilitating liver diseases such as cirrhosis or
liver cancer, and may require liver transplantation.1 HCV displays
a high degree of genetic heterogeneity and can be classified into
seven major genotypes (GT1–7) and each genotype may also con-
tain multiple subtypes. Additionally, recombinant forms of the
virus have also been identified.3 Currently, genotype 1 accounts
for almost half of all infections world-wide.2 Early treatment of
chronic HCV infection with interferon and ribavirin therapy, while
considered a breakthrough at the time, was limited by both effi-
cacy and tolerability.4 The development of a cell culture system
for HCV replication and a deeper characterization of the HCV life
cycle created new opportunities to directly target various stages
of the HCV life cycle with direct-acting antiviral agents (DAAs).5,6
The NS3/4A protease inhibitors, Boceprevir and Telaprevir, were
the first approved DAAs. When combined with interferon/ribavirin,these compounds enabled improved outcomes for patients over
interferon/ribavirin alone. The identification of and combination
of new DAAs has radically changed the HCV treatment paradigm,
enabling interferon-free regimens with significantly improved sus-
tained virologic response (SVR) rates to be available for use in the
treatment of HCV.7 While substantial progress has been made,
there still remain many HCV patients who cannot achieve a cure
with the current therapy and are in need of alternative treatment
options.
Nonstructural protein 5A (NS5A) is a viral phosphoprotein that
is essential for the replication of HCV. NS5A interacts with a num-
ber of host proteins involved in numerous cellular processes
including apoptosis, cell-cycling, innate immunity and membrane
biogenesis that can be subverted to favor viral replication. While
the exact mechanism remains unclear, NS5A plays a critical role
in viral ribonucleic acid (RNA) synthesis and virus assembly.8 As
a therapeutic target, NS5A has been validated in the clinic9 and
these studies demonstrated the utility for NS5A inhibitors in the
treatment of HCV infection.7,11 Currently four NS5A inhibitors are
available for use in HCV treatment (Fig. 1): daclatasvir (DCV),11




































































Figure 1. Clinically approved NS5A inhibitors.11–14
L. Tong et al. / Bioorg. Med. Chem. Lett. 26 (2016) 5132–5137 5133Research in this area continues to be of interest and there are a
number of NS5A inhibitors in development.6
Our research in this area identified MK-8742 (Table 1), a tetra-
cyclic indole based analog.14 The structure of MK-8742 also bearsTable 1
MK-8742 in vitro potency profile in replicons
Compd
GT1a GT1a L31V GT1
MK8742 0.006 1 28
























Scheme 1. General synthetic apsymmetrical imidazole-proline appendages on each end (Fig. 1).
In an effort to discover structurally diverse NS5A inhibitors, we
explored the impact of changing the tetracyclic indole core, to a
variety of alternative fused tetracyclic cores. Our experience in
the area of NS5A inhibitors14–16 suggested that the projection of
the imidazole appendages from the core would be an important
factor in the activity of the inhibitors and we therefore attempted
to keep the projection roughly comparable to that of our tetracyclic
indole cores.
As mentioned above, earlier core exploration demonstrated that
varied mutant inhibitory activities were observed as the shape and
make-up of the core was altered.16 Our investigation indicated that
both WT and mutant activities were dependent upon both the
specific spacing or distance between the two imidazole/proline as
well as the location of the imidazole/proline moiety in space.16
With this design objective in mind, cores were prepared varying
both the spacing and projection of the imidazole-proline group.
The alternative core analogs described in this communication were
prepared according to published patent procedures.18–20 Scheme 1
represents a general retrosynthetic approach towards the tetra-
cyclic analogs starting with the preparation of dihalogenated cores.
The two halogens were then converted to the corresponding boro-
nic esters and the advanced intermediate was coupled with 2 equiv
of a halogenated imidazole proline. Following de-protection of the
Boc groups, a double amide coupling afforded the final analogs.18–20
For screening purposes we focused on GT1a_Y93H as a measure
of tolerability of core changes. Our experience in the development
of NS5A inhibitors suggested that if candidate compounds were
potent against this mutant, they often would show similar or bet-
ter potency against other genotype 1 resistence-associated varients
(RAVs). Concurrent with GT1a_Y93H, we also selected GT1a_L31V
as it represented a RAV at a different position in the protein. In
addition to using these two RAVs as surrogates for mutant activity,
additional screening was conducted against genotypes 3a and 4a.
Table 2 summarizes activity values for various tetracyclic cores.
As a baseline for comparison versus new cores, the unsubstituted
tetracyclic indole core 1 was included for comparison.Replicon, EC9017 (nM)

























proach to core variations.
5134 L. Tong et al. / Bioorg. Med. Chem. Lett. 26 (2016) 5132–5137From Table 2, analog 2 demonstrated improvements in 2b,
GT1a_L31V and GT1a_Y93H activities versus compound 1
(GT1a_Y93H EC50 = 24 nM vs EC50 >100 nM). The chromeno-one
analog 3 demonstrated further potency improvement on
GT1a_Y93H (EC50 = 7 nM) however, it showed weaker activity ver-
sus GT1a_L31V and GT2b. Analogs 420 through 10 all showed
mutant potency similar to 1. From this group, 2 and 7were selected
as two representative cores for a scan of their pharmacokinetics (PK)
profile in rat. Table 3 summarizes the PK properties of these analogs.
Compound 7 demonstrated good rat oral bioavailability (F) 34%
while compound 2 showed reduced oral bioavailability (14%). The
encouraging replicon activity and PK profiles of these compounds
suggested that further optimization would be warranted.
Initially, we hypothesized that the differences in in vitro
potency may be related to the overall length of the cores. Cores 2
and 3 are similar in length, as compared to MK-8742 and 1, while
cores 4–10 are slightly shorter. However, the data in Table 2 wasTable 2

























































y The replicon bears methionine at position 31.
a EC50 values; ND: not determined.not supportive of this supposition. The differences in potency sug-
gested that additional functionality on the core could be important
and provided a path to improving activity. Owing to the fact that
chromen core analog 3 showed improved GT1a_Y93H profile over
1, this scaffold was chosen for follow-up.
Table 4 summarizes compounds bearing different substitutions
on the chromen core. Interestingly, the nature of the substituent
off the core played an important role in determining activities.
While a simple alkyl substitution (compound 11) showed marginal
improvement of the mutant profile, aromatic substitutions demon-
strated improved GT1a_L31V and 2b profiles. The meta-OMe-
phenyl derivative 14 not only maintained potency against
GT1a_L31V and 2b, but also significantly improved the GT1a_Y93H
activity. Figure 2 shows that from simple molecular modeling,
without knowing the active conformation, the meta-OMe phenyl
substitution of compound 14 can project into space occupied by










GT1a Y93H GT2by GT3a GT4a
>100 (>100)a 75.7 >1 0.18
>100 (24)a 24.7 >1 0.18
>50 (7)a 113 >1 0.18
57 >100 2 0.8
122.5 ND 0.69 0.31
124 100 1.59 0.76
131.7 100 0.32 0.31
685.4 ND 4.42 8.17
441.4 100 >10 4.81
360.8 100 4.69 2.48
Table 3
PK properties for alternative cores in rat








1 2 2.5/5 4.28 0.83 1.9 8.5 34
a i.v.(60% PEG200, solution), p.o. (10% tween, solution).
b i.v.(60% PEG200, solution), p.o. (0.5% methylcellulose, solution).
Table 4
Replicon profile of chromen derived cores
No. Core Replicon, EC9017 (nM)


































0.039 0.30 12.0 4.7d 1.93 ND




d Data on racemic compound; ND: not determined.
Figure 2. Overlay of MK-8742 (yellow) and compound 14 (purple).22
L. Tong et al. / Bioorg. Med. Chem. Lett. 26 (2016) 5132–5137 5135suggested that substitution on the core may contribute to potent
activities across genotypes and mutant profiles.
Next, we briefly examined the role of the substitution on the
proline ring on the overall virologic profile of a couple of tetracyclic
core variants. We had speculated that the proline ring may also
play a role in determining the mutant profiles.15,21 As a test of this
idea, fluorinated prolines were combined with core 4, with the
data summarized in Table 5. Both the mono-fluorinated proline
15 and the di-fluoro-proline 16 displayed similar GT1a_Y93H pro-
files when compared to the unsubstituted prolines in compound 4.
The positive effect of fluoro-proline in GT1a_Y93H potency, which
was previously observed,21 was not present for core 4. Also, the
addition of fluorine did not seem to improve the GT2b activity.
Core 5 was also examined with the addition of fluorine
substitutions to the proline ring (Table 6). Di-fluoro-proline 17
demonstrated moderate improved inhibitory activity against
GT1a_Y93H and GT1a_L31V when compared to the unsubstituted
Table 5













compounds 4, 15, 16
No. P Replicon, EC9017 (nM)
















0.07 20.7 30.2 >100 >10 0.6
y The replicon bears methionine at position 31.
Table 6














compounds 5 and 17
No. Proline Replicon, EC9017 (nM) Rat PK properties











0.02 17.2 22.0 341.7 3.98a 15
y The replicon bears methionine at position 31.
a Rat PK: i.v.(3 mpk, 60% PEG200, solution), p.o. (10 mpk, 10% tween, solution); ND: not determined.
5136 L. Tong et al. / Bioorg. Med. Chem. Lett. 26 (2016) 5132–5137proline 5. Fluorine substitution on the proline ring did not improve
GT2b potency. Compound 17 was evaluated in the rat where its PK
profile was comparable to compound 2 (Table 6).
In conclusion, several tetracyclic cores, distinct from that found
in MK-8742, have been identified which show genotype and
mutant activity comparable to the tetracyclic indole core. It was
demonstrated that both the overall geometric makeup of the core
and the substitutions on the core play an important role in deter-
mining in the vitro potency profiles for genotypes and RAVs. Our
efforts to further optimize and characterize these alternative cores
will be reported in the future.References and notes
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